Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Gains from Investment Securities (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Gains from Investment Securities data on record, last reported at -$6000.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 50.0% year-over-year to -$6000.0; the TTM value through Dec 2025 reached -$12000.0, up 25.0%, while the annual FY2025 figure was -$12000.0, 100.16% down from the prior year.
  • Gains from Investment Securities reached -$6000.0 in Q3 2025 per CLDX's latest filing, down from -$2000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.4 million in Q4 2023 and bottomed at -$7.1 million in Q4 2021.
  • Average Gains from Investment Securities over 5 years is $280124.7, with a median of -$1000.0 recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: surged 637992.4% in 2023, then tumbled 129.74% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at -$7.1 million in 2021, then soared by 99.99% to -$1000.0 in 2022, then soared by 637992.4% to $6.4 million in 2023, then plummeted by 100.06% to -$4000.0 in 2024, then tumbled by 50.0% to -$6000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$6000.0 in Q3 2025, -$2000.0 in Q2 2025, and -$4000.0 in Q1 2025.